People with Parkinson’s disease and cognitive impairment experience more severe symptoms and require more care but appear to use healthcare services less often, a European study has found, suggesting that new models of care are needed to better support these patients. “Healthcare should be more targeted to help this…
The Digital Medicine Society or DiMe, working with The Michael J. Fox Foundation (MJFF) and the Critical Path Institute (C-Path), has added digital tools for Parkinson’s disease research and clinical care to its library of digital health technologies. The interactive Library of Digital Measurement Products is an…
GUCY2C — a protein found mainly in the gut, but also in the brain — appears to be produced in greater amounts in Parkinson’s disease as a mechanism to protect nerve cells from damage and toxic insults, a preclinical study found. While the findings come from mice, they put…
Clumps of alpha-synuclein, the protein responsible for nerve cell death in Parkinson’s disease, initially form under medium salt conditions. However, over time, these clumps, or aggregates, transform into droplets through a process called liquid-liquid phase separation (LLPS), effectively preventing further clumping, or aggregation, of alpha-synuclein, a study has shown.
A new collaboration dubbed the Accelerating Medicines Partnership in Parkinson’s Disease and Related Disorders, or simply AMP PDRD, will work to identify specific biomarkers that can differentiate Parkinson’s from other neurodegenerative disorders with similar symptoms. The goal, according to the Foundation…
U.S. Marine Corps and Navy personnel exposed to trichloroethylene (TCE) and other industrial chemicals in drinking water at Camp Lejeune in North Carolina face greater than twice the risk of experiencing accelerated Parkinson’s disease progression than individuals who were not exposed, a new study found. These findings add to…
Dopamine-producing nerve cells, or dopaminergic neurons, in the midbrain may play a role in the temporary storage of information in short-term memory, according to new data from a mouse study. This finding challenges the traditional understanding of these nerve cells, which were previously thought to function primarily in reward processing…
An intensive course in the Lee Silverman Voice Treatment, known as LSVT Loud, may be the best strategy to help people with Parkinson’s disease overcome speech and language problems, according to a trial from the University of Birmingham in the U.K. LSVT Loud, a program of vocal exercises developed…
Once-daily treatment with IRX4204, an oral small molecule being developed by Io Therapeutics, showed a potential to safely ease motor symptoms for most adults with early Parkinson’s disease taking part in a small, 30-day study. Building on this open-label Phase 1 clinical trial (NCT02438215), the company…
The first three Parkinson’s disease patients who received a low dose of TED-A9, an investigational stem cell-based therapy being developed by S.Biomedics, saw reduced motor symptoms after a year without any reported side effects. The results come from a small Phase 1/2 clinical study (NCT05887466) where 12…
Get regular updates to your inbox.